These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9590158)

  • 1. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma.
    Duvic M; Cather J; Maize J; Frankel AE
    Am J Hematol; 1998 May; 58(1):87-90. PubMed ID: 9590158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.
    Frankel AE; Zuckero SL; Mankin AA; Grable M; Mitchell K; Lee YJ; Neville DM; Woo JH
    Curr Drug Targets; 2009 Feb; 10(2):104-9. PubMed ID: 19199905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
    Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
    J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
    Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
    Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
    Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
    Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
    J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication.
    Foss FM; Bacha P; Osann KE; Demierre MF; Bell T; Kuzel T
    Clin Lymphoma; 2001 Mar; 1(4):298-302. PubMed ID: 11707845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New advances in the management of cutaneous T-cell lymphoma.
    Young SK
    Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
    McCann S; Akilov OE; Geskin L
    Clin J Oncol Nurs; 2012 Oct; 16(5):E164-72. PubMed ID: 23022942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
    Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
    J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
    Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
    Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
    [No Abstract]   [Full Text] [Related]  

  • 14. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
    Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
    J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denileukin diftitox and vision loss.
    Ruddle JB; Prince HM
    Leuk Lymphoma; 2007 Apr; 48(4):655-6. PubMed ID: 17454621
    [No Abstract]   [Full Text] [Related]  

  • 16. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.
    Duvic M; Geskin L; Prince HM
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):377-84. PubMed ID: 23770157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma.
    Hesketh P; Caguioa P; Koh H; Dewey H; Facada A; McCaffrey R; Parker K; Nylen P; Woodworth T
    J Clin Oncol; 1993 Sep; 11(9):1682-90. PubMed ID: 8355035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
    Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
    Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
    Frankel AE; Fleming DR; Powell BL; Gartenhaus R
    Expert Opin Biol Ther; 2003 Feb; 3(1):179-86. PubMed ID: 12718740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.
    Kuzel TM; Rosen ST; Gordon LI; Winter J; Samuelson E; Kaul K; Roenigk HH; Nylen P; Woodworth T
    Leuk Lymphoma; 1993 Nov; 11(5-6):369-77. PubMed ID: 8124209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.